The regulation of blood vessel formation is critical both developmentally and in the adult. 1, 2 In the adult, normal processes such as wound healing and pathological processes such as tumor expansion and metastasis require the production of new blood vessels. We have begun to understand how blood vessel formation is regulated at the molecular level, and vascular endothelial growth factor (VEGF) is clearly central to this process. 3 Mouse embryos lacking even one copy of the VegfA gene die as embryos with vascular defects, and vascular development in differentiating embryonic stem (ES) cells is compromised in VegfAϩ/Ϫ and VegfAϪ/Ϫ ES cells in a dosedependent manner. 4 -6 Moreover, modestly elevated levels of VEGF result in vascular abnormalities, 7 and large doses of VEGF compromise both vascular development and neovascularization in adult organisms. 8, 9 These findings suggest that VEGF signaling must be precisely controlled during vascularization to result in proper vessels. The location and duration of VEGF expression provide one level of control, but other components of the pathway are also likely to be involved in fine tuning the signal.
Two high-affinity VEGF receptors, flk-1 and flt-1, are candidates to mediate fine tuning of the pathway. 10, 11 Both receptors are membrane-spanning receptor tyrosine kinases that bind VEGF-A with high affinity, but their effects on VEGF signaling are very different. Mice or ES cells lacking flk-1 have little or no blood vessel formation, suggesting that VEGF effects on endothelial cells are mediated through flk-1.
12,13 VEGF signaling through flk-1 produces several cellular responses, including a strong mitogenic signal and a survival signal for endothelial cells and their precursors. 14 -17 In contrast, VEGF binding to flt-1 does not produce a strong mitogenic signal, and flt-1Ϫ/Ϫ mice die at midgestation with vascular overgrowth and disorganization. 18, 19 We recently showed that flt-1 impacts developmental blood vessel formation by negatively modulating endothelial cell division. 20 Thus it was logical to ask whether agents that affect flk-1 signaling could rescue the phenotypic effects of the flt-1 mutation. Our results show that two agents, the potent flk-1 small molecule inhibitor SU5416 and a Flt-1/Fc chimeric protein that binds and sequesters VEGF, partially rescue the vascular overgrowth phenotype of flt-1Ϫ/Ϫ ES cell-derived blood vessels. Flk-1 tyrosine phosphorylation is elevated in the flt-1 mutant blood vessels and this increase is blocked by the flk-1 inhibitor. These results indicate that flt-1 negatively modulates developmental blood vessel formation by dampening signaling through flk-1.
Materials and Methods
Cell Culture, Differentiation, and Antibody Staining ES cells were maintained and differentiated as described. 20, 21 SU5416 was resuspended in dimethyl sulfoxide at a concentration of 10 mmol/L, and Flt-1/Fc (recombinant mouse VEGFR-1 (flt-1)/Fc; R & D Systems, Minneapolis, MN) was resuspended in phosphate-buffered saline (PBS)/0.1% bovine serum albumin at a concentration of 10 g/ml. Both solutions were added to growth medium immediately before feeding the cultures every second day from day 5 (SU5416) or day 3 (Flt-1/ Fc). Day 8 cultures were fixed in fresh cold MeOH:acetone (1:1) for 5 minutes and then processed for antibody staining as described. 20, 21 All cultures were reacted with rat anti-mouse PECAM-1 (Mec 13.3; Pharmingen B-D, San Diego, CA) at 1:1000 dilution and then with donkey anti-rat tetramethyl-rhodamine isothiocyanate (Jackson Immunoresearch, West Grove, PA) at a 1:200 dilution. Cultures were stored in PBS at 4°C. Image analysis was as described.
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Protein Analysis
Cell lysates were collected from day 7 or 8 differentiated ES cells using RIPA buffer [150 mmol/L NaCl, 50 mmol/L Tris-HCl, pH 7.5, 1% Nonidet P-40, 0.25% Na deoxycholate, 1 mmol/L Na orthovanadate, 1 mmol/L NaF, and complete mini ethylenediaminetetraacetic acid-free protease cocktail inhibitor tablets (Boehringer Mannheim, Indianapolis, IN)]. Flk-1 protein was immunoprecipitated from 6 mg of total protein with 1.5 g anti-flk polyclonal antibody (sc-504; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. Protein A agarose beads were added and the lysates incubated for 2 hours at 4°C. Immunoprecipitates were washed with RIPA buffer followed by PBS and loaded onto a 5% polyacrylamide gel. After transfer to polyvinylidene difluoride (Amersham, Arlington Heights, IL), phosphorylated flk-1 was detected by incubation with a monoclonal anti-pTyr antibody (clone PY20; BD Transduction, San Jose, CA) at 1:1000, followed by washing and detection with enhanced chemiluminescence (Amersham). The membrane was then stripped and total flk-1 was detected using anti-flk-1 antibody [sc-6251 at 1:100 (Santa Cruz Biotechnology) or no. 555307 at 1:500 (B-D Pharmingen)], and enhanced chemiluminescence detection. The signal from the upper band was quantitated by densitometry using NIH Image, and p-Tyr levels were normalized to flk-1 levels.
Results
Blockade of the Flk-1 Signaling Pathway Partially Rescues the Flt-1 Mutant Vascular Phenotype
The flk-1 signal transduction pathway was experimentally perturbed in two distinct ways ( Figure 1) . First, the selective flk-1 inhibitor SU5416 was added to ES cell cultures as they differentiated to form primitive blood vessels. SU5416 is a small molecule inhibitor that freely traverses the membrane and binds the ATP-binding pocket of flk-1, preventing phosphorylation and downstream signaling. [22] [23] [24] As expected, control wild-type cultures incubated with the inhibitor showed a severe disruption of normal blood vessel formation (compare Figure 1D ). The flt-1Ϫ/Ϫ vessels also appeared the most normal, but not completely normal, when incubated with 1 mol/L of SU5416 ( Figure 1B) . Thus, perturbation of flk-1 signaling partially rescued the flt-1 mutant vascular phenotype.
The experiment was repeated with a second inhibitor with a completely different mode of action. Flt-1/Fc is a small protein that binds and sequesters the ligand VEGF-A to prevent it from binding flk-1. 25 Because vascular development in ES cell cultures is VEGF-dependent, 6 we reasoned that modulating effective VEGF-A levels with this inhibitor might have similar effects to incubation with SU5416. This was the case, and wild-type vascular development was perturbed while flt-1Ϫ/Ϫ mutant vascular development was partially rescued by addition of Flt-1/Fc (Figure 1 ; E to G, K). Quantitation of the vascular area also showed that this partial rescue was dose-dependent, with 1 g/ml of inhibitor approximating wild-type levels of vasculature ( Figure 1H ). However, the phenotypic rescue of the flt-1 mutant vessels was less dramatic with Flt-1/Fc than with SU5416 (compare Figure  1, B and F) . Thus, perturbation of the flk-1 signal transduction pathway by two mechanistically distinct inhibitors partially rescues the flt-1 mutant vasculature, suggesting that flt-1 impinges on the flk-1 signaling pathway.
Flk-1 Tyrosine Phosphorylation Levels Correlate with the Vascular Phenotype in Flt-1 Mutant and Rescued Vessels
Because flk-1 phosphorylation is one of the first biochemical events associated with ligand engagement, we hypothesized that flk-1 phosphorylation was normally sensitive to levels of endogenous flt-1, and also that partial rescue of the flt-1 mutant vascular phenotype would be accompanied by a reduction in the level of flk-1 tyrosine phosphorylation. We immunoprecipitated flk-1 from lysates prepared from ES cell differentiation cultures, then blotted with an antibody to phosphotyrosine to determine the amount of phospho-flk. A flk-1 antibody was used to determine total levels of flk-1, and the ratio of phospho-flk to total flk-1 was calculated to control for variations in the amount of flk-1 in the different cultures (Figure 2) . The doublet seen in the flk-1 lanes represents differential 
Discussion
Although it has been known for some time that the VEGF receptor flt-1 negatively modulates blood vessel formation, 18 ,27 it has not been clear how this effect is achieved at the cellular and molecular levels. We recently showed that flt-1 negatively modulates endothelial cell proliferation during embryonic development and in differentiating ES cell cultures. 20 Here we show that this negative modulation by flt-1 impinges on the flk-1 signaling pathway by affecting the level of flk-1 tyrosine phosphorylation. The data supporting this model are that two distinct modes of perturbation of flk-1 signaling partially rescue flt-1Ϫ/Ϫ mutant blood vessel formation, and phenotypic rescue is accompanied by reduced levels of flk-1 tyrosine phosphorylation. Moreover, elevated levels of flk-1 tyrosine phosphorylation in the flt-1 mutant blood vessels show that the absence of flt-1 leads to up-regulation of the first measurable parameter of flk-1 signal transduction. This finding has implications for the molecular mechanism of flt-1 action.
Studies in cultured cells have provided evidence for two potential molecular models of flt-1 action. Signal transduction through the flt-1 receptor is thought to negatively regulate flk-1-dependent functions such as proliferation and migration. 28 -30 However, a mouse that has no wild-type flt-1 protein, but instead is homozygous for a mutant flt-1 that is missing most of its cytoplasmic domain, is viable. 31 This finding suggests that the signaling capacity of flt-1 may not be important developmentally. A soluble form of flt-1 (sflt-1) can be produced by alternative splicing, 32, 33 suggesting that one role for flt-1 involves sequestration of the VEGF ligand by sflt-1. Our data do not rigorously distinguish between these models, but the finding that flk-1 tyrosine phosphorylation is elevated in the flt-1 mutant background strongly indicates that an early step in flk-1 signal transduction is the target of flt-1 action developmentally. This is consistent with a model whereby flt-1 acts as a sink to modulate the amount of VEGF ligand available to bind to flk-1. Thus in the absence of flt-1 more ligand is available to bind flk-1, and the first step of signal transduction, receptor tyrosine phosphorylation, is up-regulated. This up-regulation is predicted to lead to increased signaling through all of the numerous pathways that are affected by flk-1 signal transduction, including proliferation, survival, migration, and permeability.
This is the first demonstration that the vascular overgrowth seen in the absence of flt-1 can be modulated by manipulations of the flk-1 pathway. The inability to completely rescue the flt-1 mutant phenotype with either inhibitor suggests that either flt-1 impinges on pathways other than flk-1 signaling, or that the inhibitors cannot act optimally. We favor the latter hypothesis because several studies show that rigorous control of the amplitude and timing of VEGF signaling in local environments is required for proper vascular development. 4,6 -8 In this context, the increased efficacy of the small molecule inhibitor in rescue relative to the Flt-1/Fc protein may result from deposition of some endogenous VEGF into local matrix, where it may be inaccessible for sequestration by Flt-1/Fc. Alternatively, Flt-1/Fc may incompletely rescue the flt-1 mutant phenotype because it is not spatially and/or temporally regulated properly. Recent studies suggest that a VEGF gradient may be important for proper vessel formation, 34, 35 and we have recently demonstrated that flt-1 affects vessel morphogenesis (JP Kearney et al, in press). Thus flt-1 may normally affect presentation of VEGF in a spatial context that is not reproduced by exogenous administration of Flt-1/Fc. In any case, the data presented here provides further understanding of how the organism normally modulates critical parameters of blood vessel formation. Two high-affinity VEGF receptors have opposing effects on this process. Moreover, the negative modulation by flt-1 impinges on flk-1 signaling at an early step in the pathway, suggesting that all downstream effects of this pathway are tightly modulated as new blood vessels form. 26 The reproducible increase in the mobility of the upper band in the presence of SU5416 is unexplained but documented in several other studies. 22, 36 members of the Bautch Lab and the Carolina Cardiovascular Biology Center for fruitful discussions.
